Imunon (IMNN) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 23, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	Celsion Corp
Entity Central Index Key	749,647
Trading Symbol	clsn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		55,466,492
Entity Public Float			$ 32
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,624,162	$ 9,265,144
Investment securities – available for sale, at fair value	1,680,000	10,799,890
Accrued interest receivable on investment securities	4,008	26,729
Advances and deposits on clinical programs	89,186	89,186
Other current assets	115,222	100,367
Total current assets	4,512,578	20,281,316
Property and equipment (at cost, less accumulated depreciation and Amortization)	462,836	854,872
Other assets:
In-process research and development	22,766,491	24,210,514
Other intangible assets, net	1,022,924	1,591,214
Goodwill	1,976,101	1,976,101
Security deposit on letter of credit	100,000	100,000
Other assets	8,761	14,386
Total other assets	25,874,277	27,892,215
Total assets	30,849,691	49,028,403
Current liabilities:
Accounts payable - trade	2,878,978	2,830,227
Other accrued liabilities	2,483,756	1,919,769
Notes payable - current portion	2,560,553	4,073,716
Deferred revenue – current portion	500,000	500,000
Total current liabilities	8,423,287	9,323,712
Earn-out milestone liability	13,188,226	13,921,412
Note payable – non-current portion		2,350,018
Deferred revenue – non-current portion	2,500,000	3,000,000
Other liabilities – non-current	12,352	47,597
Total liabilities	24,123,865	28,642,739
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at December 31, 2016 and 2015, respectively)
Common stock - $0.01 par value (112,500,000 shares authorized; 31,226,336 and 23,395,211 shares issued at December 31, 2016 and 2015 and 31,221,657 and 23,319,287 shares outstanding at December 31, 2016 and 2015, respectively)	312,263	233,952
Additional paid-in capital	247,878,463	239,668,235
Accumulated other comprehensive loss		(3,858)
Accumulated deficit	(241,379,712)	(218,130,360)
Total stockholders’ equity before treasury stock	6,811,014	21,767,969
Treasury stock, at cost (4,679 and 75,924 shares at December 31, 2016 and 2015, respectively)	(85,188)	(1,382,305)
Total stockholders’ equity	6,725,826	20,385,664
Total liabilities and stockholders’ equity	$ 30,849,691	$ 49,028,403

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	112,500,000	112,500,000
Common stock, shares issued (in shares)	31,226,336	23,395,211
Common stock, shares outstanding (in shares)	31,221,657	23,319,287
Treasury stock, shares (in shares)	4,679	75,924

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Licensing revenue	$ 500,000	$ 500,000
Operating expenses:
Research and development	14,623,068	14,659,941
General and administrative	6,526,752	6,686,852
Total operating expenses	21,149,820	21,346,793
Loss from operations	(20,649,820)	(20,846,793)
Other income (expense):
Gain (loss) from valuation of earn-out milestone liability	733,186	(257,702)
Loss from valuation of common stock warrant liability		(61,246)
Investment income, net	26,922	63,588
Interest expense	(722,993)	(1,357,182)
Other income (expense)	3,002	(1,749)
Total other expense	(1,403,906)	(1,614,291)
Net loss	$ (22,053,726)	$ (22,461,084)
Net loss per common share – basic and diluted (in dollars per share)	$ (0.85)	$ (1.03)
Weighted average common shares outstanding – basic and diluted (in shares)	25,956,751	21,813,228
In-Process Research and Development [Member]
Other income (expense):
Loss from impairment of in-process research and development	$ (1,444,023)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (22,053,726)	$ (22,461,084)
Realized loss (gain) on investment securities recognized in investment income, net	532	(264)
Unrealized gain on investment securities	3,326	12,438
Other comprehensive income	(3,858)	(12,174)
Comprehensive loss	$ (22,049,868)	$ (22,448,910)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (22,053,726)	$ (22,461,084)
Depreciation and amortization	1,022,829	424,966
Change in fair value of earn-out milestone liability	(733,186)	257,702
Change in fair value of common stock warrant liability		61,246
Stock-based compensation	1,511,023	1,849,811
Shares issued out of treasury	101,491	86,730
Amortization of deferred finance charges and debt discount associated with note payable	236,666	438,717
Amortization of patent license fee	5,625	7,500
Change in deferred rent liability	(35,245)	(29,810)
Loss (gain) realized on sale of investment securities	532	(264)
Interest receivable on investments	22,721	183,301
Other current assets	(14,855)	246,401
Accounts payable	48,751	(859,183)
Deferred revenue	(500,000)	(500,000)
Other accrued liabilities	563,987	(536,596)
Net cash used in operating activities	(18,379,364)	(20,830,563)
Cash flows from investing activities:
Purchases of investment securities	(4,511,784)	(21,074,871)
Proceeds from sale and maturity of investment securities	13,635,000	34,460,825
Refund on security for letter of credit		50,000
Purchases of property and equipment	(62,503)	(109,341)
Net cash provided by investing activities	9,060,713	13,326,613
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	6,775,016	7,736,443
Proceeds from exercise of common stock warrants	2,500
Principal payments on note payable	(4,099,847)	(3,654,230)
Net cash provided by financing activities	2,677,669	4,082,213
Decrease in cash and cash equivalents	(6,640,982)	(3,421,737)
Cash and cash equivalents at beginning of period	9,265,144	12,686,881
Cash and cash equivalents at end of period	2,624,162	9,265,144
Cash paid for:
Interest	486,327	918,465
Income taxes
In-Process Research and Development [Member]
Cash flows from operating activities:
Impairment of in-process research and development	$ 1,444,023

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders Equity - USD ($)	Direct and ATM [Member]Common Stock [Member]	Direct and ATM [Member]Additional Paid-in Capital [Member]	Direct and ATM [Member]Treasury Stock [Member]	Direct and ATM [Member]AOCI Attributable to Parent [Member]	Direct and ATM [Member]Retained Earnings [Member]	Direct and ATM [Member]	Direct [Member]Common Stock [Member]	Direct [Member]Additional Paid-in Capital [Member]	Direct [Member]Treasury Stock [Member]	Direct [Member]AOCI Attributable to Parent [Member]	Direct [Member]Retained Earnings [Member]	Direct [Member]	Common Stock Warrants [Member]Common Stock [Member]	Common Stock Warrants [Member]Additional Paid-in Capital [Member]	Common Stock Warrants [Member]Treasury Stock [Member]	Common Stock Warrants [Member]AOCI Attributable to Parent [Member]	Common Stock Warrants [Member]Retained Earnings [Member]	Common Stock Warrants [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014																			19,984,203		113,400
Balance at Dec. 31, 2014																			$ 200,976	$ 229,778,703	$ (2,064,609)	$ (16,032)	$ (195,073,702)	$ 32,825,336
Net loss																							(22,461,084)	(22,461,084)
Registered Direct and ATM common stock offerings (in shares)	3,283,608																		14,000
Registered Direct and ATM common stock offerings	$ 32,836	$ 7,703,607				$ 7,736,443
Expiration of reset provision of the common stock warrants issued in connection with the November 2013 Hercules Loan																				336,254				336,254
Unrealized gain on investment securities																						12,174		12,174
Stock-based compensation expense																				1,828,896				1,828,896
Issuance of restricted stock																			$ 140	20,775				20,915
Issuance of common stock out of treasury (in shares)																			37,476		(37,476)
Issuance of common stock out of treasury																					$ 682,304		(595,574)	86,730
Balance (in shares) at Dec. 31, 2015																			23,319,287		75,924
Balance at Dec. 31, 2015																			$ 233,952	239,668,235	$ (1,382,305)	(3,858)	(218,130,360)	20,385,664
Realized and unrealized gains and losses, net, on investments securities																								12,174
Net loss																							(22,053,726)	(22,053,726)
Registered Direct and ATM common stock offerings (in shares)							7,454,607												126,518
Registered Direct and ATM common stock offerings							$ 74,546	$ 6,700,470				$ 6,775,016
Stock-based compensation expense																				1,332,838				1,332,838
Issuance of restricted stock																			$ 1,265	176,920				178,185
Issuance of common stock out of treasury (in shares)																			71,245		(71,245)
Issuance of common stock out of treasury																					$ 1,297,117		(1,195,626)	101,491
Balance (in shares) at Dec. 31, 2016																			31,221,657		4,679
Balance at Dec. 31, 2016																			$ 312,263	247,878,463	$ (85,188)		(241,379,712)	6,725,826
Conversion of common stock warrants (in shares)													250,000
Conversion of common stock warrants													$ 2,500					$ 2,500
Realized and unrealized gains and losses, net, on investments securities																						$ 3,858		$ 3,858

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Description of Business Celsion Corporation, a Delaware corporation based in Lawrenceville, New Jersey, and its wholly owned subsidiary, CLSN Laboratories, Inc., also a Delaware corporation, referred to herein as “Celsion”, “we”, or “the Company,” as the context requires, is a fully-integrated, development stage oncology drug company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Our lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Our pipeline also includes GEN- 1, three Basis of Presentation The accompanying consolidated financial statements of Celsion have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States and include the accounts of the Company and CLSN Laboratories, Inc. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from these estimates. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these consolidated financial statements have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business. Revenue Recognition At the inception of each collaborative agreement that includes milestone payments, the Company evaluates whether each milestone is substantive on the basis of the contingent nature of the milestone, specifically reviewing factors such as the scientific and other risks that must be overcome to achieve the milestone, as well as the level of effort and investment required. Milestones that are not considered substantive and that do not meet the separation criteria are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Payments received or reasonably assured after performance obligations are met completely are recognized as earned. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three Fair Value of Investment Securities The carrying values of investment securities approximate their respective fair values. Short Term Investments The Company classifies its investments in marketable securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments - Debt and Equity Securities Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three seven $455,000 $425,000 December 31, 2016 2015, The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature. In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, 5, Patent Licenses The Company has purchased several licenses for rights to patented technologies. Patent license costs of $75,000 December 31, 2016 2015, $75,000 $69,375, 10 Comprehensive Income (Loss) ASC 220, Comprehensive Income 220 Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss Per Common Share Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the year ended December 31, 2016, 23,831,883. 10 1,850,000 December 31, 2016, 21,984,210 For the year ended December 31, 2015, 8,116,015. December 31, 2015, Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, Stock-Based Compensation Compensation costs for all stock-based awards are measured at fair value on the date of the grant and recognized over the service period for awards expected to vest. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the current estimates, such amounts will be recorded as cumulative adjustments in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Reclassifications Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These classifications had no impact on net loss, stockholders’ equity or cash flows as previously reported. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations. In May 2014, 2014 09 606),” . The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU 2014 09 January 1, 2017; 2015 14, 606) 2014 09 one January 1, 2018. March 2016, 2016 8, 606): 2014 09 2014 09. April 2016, 2016 10, may In August 2014, ASU No. 2014 15, one one December 15, 2016. In April 2015, 2015 03 835 30). 835 30 January 1, 2016 $3,517 $26,131 December 31, 2016 December 31, 2015, In January 2016, 2016 01, December 15, 2017. In February 2016, 2016 02, 842), twelve December 15, 2018, In March 2016, 2016 09, 718). December 15, 2016,

Note 2 - Financial Condition an

Note 2 - Financial Condition and Going Concern	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s product candidates, and applications and submissions to the Food and Drug Administration. We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2016, $22.1 $18.4 $241 December 31, 2016, $4.3 The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company’s ability to achieve profitability is dependent upon its ability to obtain governmental approvals, produce, and market and sell its new product candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The operating results of the Company have fluctuated significantly in the past. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company’s control. The Company will need substantial additional funding in order to complete the development, testing and commercialization of its oncology product candidates and we have made a significant commitment to heat-activated liposome research and development projects. It is our intention at least to maintain the pace and scope of these development activities. The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company’s business plan including, but not limited to: ● the Company’s financial position for the year ended December 31, 2016; ● significant events and transaction the Company has entered into since December 31, 2016; ● the Company’s cash flow and cash usage forecasts for the period one 10 ● the impact of the monthly payments of the note payable totaling $2.6 December 31, 2016; ● the Company’s capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and ● continued support of the Company’s stockholders and lender. As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve December 31, 2016 A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives: ● on February 14, 2017, $5.0 18); ● the Company will request an increase of its authorized shares sufficient to allow for the funding of its clinical programs at its next Annual Meeting of Stockholders; ● the Company has $7.5 10) ● it has assessed its current expenditures and will be reducing the current spending requirements where necessary; ● it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities; ● it will pursue possible partnerships and collaborations; and ● it will pursue potential out licensing for its drug candidates. Our ability to continue as a going concern may twelve

Note 3 - Short Term Investments

Note 3 - Short Term Investments Available for Sale	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	3. Short term investments available for sale of $1,680,000 $10,799,890 December 31, 2016 2015, Securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized. A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: December 31, 201 6 December 31, 201 5 Cost Fair Value Cost Fair Value Short-term investments Certificate of deposit $ 1,680,000 $ 1,680,000 $ 4,800,000 $ 4,798,810 Bonds - corporate issuances – – 6,003,748 6,001,080 Total short-term investments $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890 December 31, 201 6 December 31, 201 5 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890 Between 3-12 months – – – – Total $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890 Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: 201 6 201 5 Interest and dividends accrued and paid $ 31,262 $ 186,322 Accretion of investment premium (3,808 ) (122,998 ) (Losses) gains on investment maturity and sales, net (532 ) 264 Investment income net $ 26,922 $ 63,588 The following table shows the Company’s investment securities gross unrealized losses and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2015. December 31, 2016, $1,680,000 no December 31, 2016. December 31, 201 5 Description of Investment Securities Fair Value Unrealized Holding Gains (Losses) Available for sale (all unrealized holding gains and losses are less than 12 months at date of measurement) Short-term investments with unrealized gains – Certificates of deposit $ 240,024 $ 24 Short-term investments with unrealized losses – Certificates of deposit 4,558,786 (1,214 ) Short-term investments with unrealized losses – Bonds - corporate issuances 6,001,080 (2,668 ) Total $ 10,799,890 $ (3,858 )

Note 4 - Fair Values of Financi

Note 4 - Fair Values of Financial Instruments	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. FASB Accounting Standards Codification (ASC) Section 820, Fair Value Measurements and Disclosures, three three may Level 1: Level 2: 1 Level 3: The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 2 Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheets at their estimated fair values primarily due to their short-term nature. There were no 1 2 no 3 2016 2015 Assets and liabilities measured at fair value are summarized below: Total Fair Value on the Balance Sheet Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2016 Investment securities, available for sale $ 1,680,000 $ 1,680,000 $ ─ $ ─ Recurring items as of December 31, 2015 Investment securities, available for sale $ 10,799,890 $ 10,799,890 $ ─ $ ─ Liabilities: Recurring items as of December 31, 2016 Earn-out milestone liability (Note 12) $ 13,188,226 $ ─ $ ─ $ 13,188,226 Recurring items as of December 31, 2015 Earn-out milestone liability (Note 12) $ 13,921,412 $ ─ $ ─ $ 13,921,412

Note 5 - Acquisition of EGEN, I

Note 5 - Acquisition of EGEN, Inc.	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Business Combination Disclosure [Text Block]	5. On June 20, 2014, The total aggregate purchase price for the acquisition is up to $44.4 $30.4 $3.0 2,712,188 1933, 4(2) 670,070 333 198786) September 16, 2014 September 30, 2014 The Earn-Out Payments of up to $30.4 ● $12.4 1 ● $12.0 1 ● Up to $6.0 On June 9, 2014, $5 November 25, 2013, 8). The EGEN Purchase Agreement contains customary representations and warranties regarding EGEN and Celsion, covenants regarding the conduct of EGEN’s business prior to the consummation of the acquisition, indemnification provisions, termination and other provisions customary for transactions of this nature. The acquisition of EGEN was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. The fair value of the consideration transferred for the acquisition was approximately $27.6 Property and equipment, net $ 35,000 In-process research and development 24,211,000 Other Intangible assets (Covenant not to compete) 1,591,000 Goodwill 1,976,000 Total assets: 27,813,000 Accounts payable and accrued liabilities (235,000 ) Net assets acquired $ 27,578,000 Acquired in-process research and development (IPR&D) consists of EGEN's drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&D drug technology platforms was estimated to be $24.2 third September 30, ● As of September 30, 2016, ● At December 31, 2016, one may impaired. After reassessment of the September 30, 2016 $1.4 $1.4 fourth 2016. $0.7 December 31, 2016. Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants (“Covenant Not To Compete”) to the Company whereby EGEN agreed, during the period ending on the seventh June 20, 2014, At the end of 2016, $1.6 7 fourth 2016, $568,290 2016. $1,022,924 $568,290 December 31, 2016 $1,591,214 December 31, 2015. Following is a schedule of future amortization amounts during the remaining life of the Covenant Not To Compete. Year Ended December 31, 2017 $ 227,316 2018 227,316 2019 227,316 2020 227,316 2021 113,660 Total $ 1,022,924 The purchase price exceeded the estimated fair value of the net assets acquired by approximately $2.0 third September 30 ● As of September 30, 2016, two ● At December 31, 2016, 2), 1 2,

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Year E nded December 31, 201 6 201 5 Machinery and equipment (5-7 year life) $ 2,459,532 $ 2,398,613 Furniture and fixtures (3-5 year life) 246,507 244,923 Leasehold improvements (5-7 year life) 269,819 269,819 2,975,858 2,913,355 Less accumulated depreciation and amortization (2,513,022 ) (2,058,483 ) Total $ 462,836 $ 854,872

Note 7 - Other Accrued Liabilit

Note 7 - Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Other accrued liabilities at December 31, 2016 2015 Year E nded December 31, 2016 2015 Amounts due to contract research organizations and other contractual agreements $ 1,115,193 $ 571,615 Accrued payroll and related benefits 1,066,751 947,078 Accrued professional fees 259,550 319,200 Accrued interest on notes payable 22,241 62,136 Other 20,021 19,740 Total $ 2,483,756 $ 1,919,769

Note 8 - Notes Payable

Note 8 - Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Hercules Credit Agreement In November 2013, $20 first $5 November 2013 $4 June 10, 2014, second $5 $3.0 second $10 The obligations under the Hercules Credit Agreement are in the form of secured indebtedness bearing interest at a calculated prime-based variable rate (11.25% December 17, 2015, 11.50% December 18, 2015 December 15, 2016 11.75% first twelve 30 June 1, 2017. In connection with the Hercules Credit Agreement, the Company incurred cash expenses of $122,378 $230,000 As a fee in connection with the Hercules Credit Agreement, the Company issued Hercules a warrant for a total of 97,493 $3.59, November 25, 2013. second June 10, 2014, 97,493 November 25, 2018. November 25, 2013. may 144 first 415 1933 333 193936 September 30, 2014. The Company valued the Hercules Warrant issued at the inception of the loan using the Black-Scholes option pricing model and recorded $521,763 2013 102%, 1.37%, 5 $3.55 second 2014, $521,763. 97,493 $260,928 second $5 June 9, 2014, 97,493 $215,333 June 10, 2014, 104%, 1.69%, 4.5 $3.07 June 9, 2014) 2014, In the second 2015, $336,254 $18,018 $61,246 second 2015, zero $336,254 Also in connection with each of the $5.0 3.5% $350,000 For the year ended December 31, 2016, $486,327 $236,666 December 31, 2015, $918,465 $438,717 The Hercules Credit Agreement contains customary covenants, including covenants that limit or restrict the Company’s ability to grant liens, incur indebtedness, make certain restricted payments, merge or consolidate and make dispositions of assets. Upon the occurrence of an event of default under the Hercules Credit Agreement, the lenders may Following is a schedule of future principle payments and end of term fee net of debt discount due on the Hercules Credit Agreement: As of December 31, 2017 $ 2,560,553 2018 and thereafter – Total $ 2,560,553

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. A reconciliation of the Company’s statutory tax rate to the effective rate for the years ended December 31, 2016 2015 2016 2015 Federal statutory rate 34.0 % 34.0 % State taxes, net of federal tax benefit 5.5 5.5 Recapture of alternative minimum tax – – Valuation allowance (39.5 ) (39.5 ) Effective tax rate – % – % The components of the Company’s deferred tax asset as of December 31, 2016 2015 December 31, In thousands 2016 2015 Net operating loss carry forwards $ 80,920 $ 71,557 Deferred tax assets, net 2,489 4,953 Subtotal 83,409 76,510 Valuation allowance (83,409 ) (76,510 ) Total deferred tax asset $ - $ - The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company’s ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. At this time, the Company has established a valuation reserve for all of its deferred tax assets. Such tax assets are available to be recognized and benefit future periods. Following is a schedule of net operating loss carry forwards and their year of expiration: Approximate Amount of Unused Operating Loss Carry Forwards (in $000s) Expiration During Year Ended $ 7,136 2023 15,647 2024 8,168 2025 7,361 2026 11,905 2028 18,547 2029 18,145 2030 21,386 2031 20,558 2032 10,321 2033 22,906 2034 21,338 2035 21,444 2036 $ 204,862 During 2016, 2015 382 382, July 25, 2011, February 5, 2013, June 3, 2013 June 1, 2015. December 31, 2016, $85.6 382 382 $4.9 $90 July 25, 2011, $1.4 $34 July 2011 February 5, 2013, $1.5 $34 February 5, 2013 June 3, 2013 $1.6 $31 June 3, 2013 June 1, 2015. may 382

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. In September 2015, $75 3 2015 333 206789) September 25, 2015. At the 2016 June 2016, 75,000,000 112,500,000 100,000 may 112,600,000 We did not 2015 2016 June 2016 On June 13, 2016, June 2016 June 2016 2,311,764 $1.36 2,100,000 9.99% June 2016 2015 $6.0 June 2016 third 2016, 250,000 December 31, 2016, 1,850,000 December 31, 2016, In a concurrent private placement (the June 2016 June 2016 0.5 June 2016 one June 2016 0.5 June 2016 June 2016 six five one June 2016 six one June 2016 June 2016 six five one June 2016 $1.40 8,823,528 June 2016 4.99% 61 may 9.99%. June 2016 June 2016 1933, 2015 4(a)(2) 506(b) October 31, 2016 1 June 2016 June 2016 144 June 2016 may 144 June 2016 Under the June 2016 six December 2016 On December 20, 2016, December 2016 December 2016 5,142,843 $0.35 $1.8 2015 In a concurrent private placement (the December 2016 one December 2016 December 2016 six five one December 2016 $0.46 5,142,843 December 2016 9.99% 61 may 9.99%. The December 2016 December 2016 2015 4(a)(2) 506(b) 1 December 2016 December 2016 144 December 2016 may 144 December 2016 Under the December 2016 three 1. May 2015 Common Stock Offering On May 27, 2015, June 1, 2015, May 2015 3,000,000 $2.675 $8.0 3 333 183286), August 13, 2012, August 20, 2012, September 14, 2012 In a concurrent private placement closed on June 1, 2015, May 2015 May 2015 $2.60 May 2015 0.65 May 2015 1,950,000 May 2015 five July 10, 2015, May 2015 3 333 205608) July 30, 2015. Under this purchase agreement, the Company was prohibited, for the period from the date of closing and ending September 1, 2015, five January 2014 On January 15, 2014, 3,603,604 $0.01 1,801,802 $15 January 2014 one 0.25 0.25 $4.1625. five one January 2015. $4.10 nine Shares issued in acquisition of EGEN, Inc. The Company issued 2,712,188 1933, 4(2) 670,070 415 1933, 333 198786 September 30, 2014. Controlled Equity Offering On February 1, 2013, SM may $25.0 3. may 415 1933, February 1, 2013 December 31, 2016, 1,479,535 $7.6 The Company is not obligated to sell any ATM Shares under the ATM Agreement. Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company may may The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregate offering price of $25 may 10 3.0% $50,000 January 2014 June 23, 2017. On October 2, 2015, 2015 may $7,500,000 The Company currently has approximately $17.4

Note 11 - Stock Based Compensat

Note 11 - Stock Based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. - BASED COMPENSATION Employee Stock Options The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options may one five ten 2001 In 2001, “2001 148,148 2001 2004 In 2004, “2004 148,148 2004 2004 2004 2004 2014, 10 Any options forfeited or terminated under the 2001 2004 2007 2007 In 2007, 2007 “2007 222,222 2007 2007 June 25, 2010, June 7, 2012 June 20, 2014, 2007 2007 2007 2007 222,222 444,444 2010, 500,000 944,444 2012 2,500,000 3,444,444 2014. The Company has issued stock awards to employees, directors and vendors out of the stock option plans. Options are generally granted with strike prices equal to the market value on the date of the grant. Incentive stock options may 100% 10% 110% may may Option awards vest upon terms determined by the Board of Directors. Restricted stock awards, performance stock awards and stock options are subject to accelerated vesting in the event of a change of control. The Company issues new shares to satisfy its obligations from the exercise of options. In 2007 95,555 four January 2017. As of December 31, 2016, 3,533,752 2,999,663 534,089 Total compensation cost charged related to employee stock options and non-vested restricted stock awards amounted to $1.5 $1.8 December 31, 2016 2015, No December 31, 2016, $0.3 0.7 December 31, 2016 2015 $1.16 $2.05, Equity Awards Issued to Consultants for Services The Company periodically issues equity awards to consultants in exchange for services provided. The fair value of options granted is measured in accordance with ASC 718, Compensation – Stock Compensation, may 10 December 31, 2016 2015. A summary of stock option awards as of December 31, 2016 two December 31, 2016, Stock Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2015 1,744,755 $ 7.20 Granted 839,250 2.35 Canceled or expired (444,183 ) 5.56 Outstanding at December 31, 2015 2,139,822 $ 5.64 Granted 846,283 1.29 Canceled or expired (53,442 ) 9.71 Outstanding at December 31, 2016 2,932,663 4.31 7.2 $ - Exercisable at December 31, 2016 2,198,907 $ 5.09 6.9 $ - A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2016 two December 31, 2016, Restricted Stock Number Outstanding Weighted Average Exercise Price Non-vested stock awards outstanding at January 1, 2015 7,018 $ 3.32 Granted 88,500 2.60 Vested and issued (14,000 ) 2.72 Non-vested stock awards outstanding at December 31, 2015 81,518 $ 2.64 Granted 112,000 1.63 Vested and issued (126,518 ) 1.72 Non-vested stock awards outstanding at December 31, 2016 67,000 * $ 2.67 * The non-vested restricted stock awards as of December 31, 2016 0.7 $21,000. A summary of stock options outstanding at December 31, 2016 Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price $1.00 to 2.99 1,560,699 8.9 $ 1.77 857,897 8.9 $ 1.78 3.00 to 5.99 890,857 7.2 $ 3.81 859,903 7.2 $ 3.69 6.00 to 12.99 322,387 3.0 $ 10.82 322,387 3.0 $ 10.82 13.00 to 19.99 88,856 3.4 $ 14.19 88,856 3.4 $ 14.19 Above $20.00 69,864 1.2 $ 24.85 69,864 1.2 $ 24.85 2,932,663 2,198,907 The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s nonqualified stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: Year Ended December 31, 201 6 201 5 Risk-free interest rate 1.55 to 1.87 % 1.57 to 2.93 % Expected volatility 87.5 - 89.1 % 92.9 - 104.1 % Expected life (in years) 10 10 Expected forfeiture rate 5 % 5 % Expected dividend yield 0.0 % 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury strips as published in the Wall Street Journal in effect at the time of grant. The model incorporates exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data. The expected life of the fiscal 2016 2015 107.

Note 12 - Earn-out Milestone Li

Note 12 - Earn-out Milestone Liability	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Earn-out Milestone Liability Disclosure [Text Block]	12. The total aggregate purchase price for the EGEN Acquisition included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 $13.9 June 20, 2014 (10% 67%) (1.5 2.5 At December 31, 2016, $13.2 $0.7 2016 $13.9 December 31, 2015. 2016, $0.7 fourth 2016 one 5) December 31, 2016 (50% 80%) (2.0 2.5 December 31, 2015, $13.9 $257,702 2015 $13.7 June 30, 2015. December 31, 2015 (10% 67%) (1.2 6.5 The following is a summary of the changes in the earn-out milestone liability for 2015 2016: Balance at January 1, 2015 $ 13,663,710 Non-cash loss from the adjustment for the change in fair value included in 2015 net loss 257,702 Balance at December 31, 2015 $ 13,921,412 Non-cash gain from the adjustment for the change in fair value included in 2016 net loss (733,186 ) Balance at December 31, 2016 $ 13,188,226

Note 13 - Warrants

Note 13 - Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Warrants [Text Block]	13. As more fully described in Note 10, 2016 2015 16,066,371 1,950,000 November 2013 8, 194,986 not 2015 2016 250,000 third 2016 10. Following is a summary of all warrant activity for the two December 31, 2016: Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2015 5,069,815 $ 8.18 Warrants issued in connection with the May 2015 equity transaction 1,950,000 $ 2.60 Warrants expired during 2015 (1,125,140 ) $ 7.98 Warrants outstanding at December 31, 2015 5,894,675 $ 6.37 Warrants issued in connection with the 2016 equity transactions 16,066,371 $ 0.92 Warrants exercised during 2016 (250,000 ) $ 0.01 Warrants expired during 2016 (879,163 ) $ 14.94 Warrants outstanding at December 31, 2016 20,831,883 $ 1.88 Aggregate intrinsic value of outstanding warrants at December 31, 2016 $ 534,000 Weighted average remaining contractual terms (years) 3.32 (1) (1) Does not include the remaining Pre-Funded Warrants issued in the June 2016 1,850,000

Note 14 - Celsion Employee Bene

Note 14 - Celsion Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	14. Celsion maintains a defined-contribution plan under Section 401(k) 21. may fourth 2008, 3% December 31, 2016 2015 $82,391 $80,408

Note 15 - Licenses of Intellect

Note 15 - Licenses of Intellectual Property and Patents	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	15. On November 10, 1999, 20 The total number of shares issuable to Duke under these provisions is subject to adjustment in certain cases, and Duke has piggyback registration rights for public offerings taking place more than one January 31, 2003, 253,691 $2.2 For the years ended December 31, 2016 2015, Under the November 1999 The Company has licensed from Valentis, CA certain global rights covering the use of pegylation for temperature sensitive liposomes. In addition to the rights available to the Company under completed or pending license agreements, the Company is actively pursuing patent protection for technologies developed by the Company. Among these patents is a family of pending US and international patent applications which seek to protect the Company’s proprietary method of storing ThermoDox® which is critical for worldwide distribution channels. ThermoDox® is a registered trademark in the U.S., Argentina, Australia, Canada, China, Columbia, the European Communities: (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK), Hong Kong, Israel, Japan, New Zealand, Peru, Philippines, Russia, Singapore, South Korea and Taiwan. The Company has registered transliterations of ThermoDox® in China, Hong Kong, Japan, Singapore, South Korea and Taiwan. The Company has an additional 14 Finally, through proprietary information agreements with employees, consultants and others, the Company seeks to protect its own proprietary know-how and trade secrets. The Company cannot offer assurances that these confidentiality agreements will not be breached, that the Company will have adequate remedies for any breach, or that these agreements, even if fully enforced, will be adequate to prevent third third

Note 16 - Technology Developmen

Note 16 - Technology Development and Licensing Agreements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Licensing Transaction [Text Block]	16. On May 7, 2012 three first 2015, three $685,787 March 2015. April 2015. On January 18, 2013, $5 ® January 31, 2013 January 18, 2013 ® $5.0 first 2013 10 ® On July 19, 2013, Among the key provisions of the Celsion-Hisun Memorandum of Understanding are: ● Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory; ● Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and ● Hisun will be granted a right of first On August 8, 2016, 1 1, 12 1 1 1 first Key provisions of the GEN- 1 ● the GEN- 1 1 ● once approved, the cost structure for GEN- 1 ● Celsion will provide Hisun a certain percentage of China’s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval; ● Hisun and Celsion will commence technology transfer activities relating to the manufacture of GEN- 1, ● Hisun will collaborate with Celsion around the regulatory approval activities for GEN- 1

Note 17 - Contingent Liabilitie

Note 17 - Contingent Liabilities and Commitments	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	17. In July 2011, 10,870 October 2011, 66 6 first $23,000 April 2012. $250,000, $50,000 19th, 31st 43rd $100,000 three $50,000 April 2013 2014 2015, $ 50,000 2015, 30%. In connection with the EGEN Asset Purchase agreement in June 2014, 11,500 13 $23,200 The Company paid $575,516 $570,078 2016 2015, one December 31, 2016: For the year ending December 31: Operating Leases 2017 $ 378,042 2018 23,200 2019 — 2020 and beyond — Total minimum lease payments $ 401,242

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	18. On February 14, 2017, February 14, 2017 19,385,869 $0.23 16,489,402 2,600,000 $0.23 five $0.22 $0.01 9.99% $5.0 February 14, 2017 In connection with the February 14, 2017 1 333 215321) December 23, 2016, 1 January 20, 2017, 2 February 13, 2017, 3 February 13, 2017 4 February 14, 2017 1933,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements of Celsion have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States and include the accounts of the Company and CLSN Laboratories, Inc. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from these estimates. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these consolidated financial statements have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition At the inception of each collaborative agreement that includes milestone payments, the Company evaluates whether each milestone is substantive on the basis of the contingent nature of the milestone, specifically reviewing factors such as the scientific and other risks that must be overcome to achieve the milestone, as well as the level of effort and investment required. Milestones that are not considered substantive and that do not meet the separation criteria are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Payments received or reasonably assured after performance obligations are met completely are recognized as earned.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Investment Securities The carrying values of investment securities approximate their respective fair values.
Investment, Policy [Policy Text Block]	Short Term Investments The Company classifies its investments in marketable securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments - Debt and Equity Securities
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three seven $455,000 $425,000 December 31, 2016 2015, The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may
Deposits [Policy Text Block]	Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, 5, Patent Licenses The Company has purchased several licenses for rights to patented technologies. Patent license costs of $75,000 December 31, 2016 2015, $75,000 $69,375, 10
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income 220
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the year ended December 31, 2016, 23,831,883. 10 1,850,000 December 31, 2016, 21,984,210 For the year ended December 31, 2015, 8,116,015. December 31, 2015,
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes,
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Compensation costs for all stock-based awards are measured at fair value on the date of the grant and recognized over the service period for awards expected to vest. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the current estimates, such amounts will be recorded as cumulative adjustments in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These classifications had no impact on net loss, stockholders’ equity or cash flows as previously reported.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations. In May 2014, 2014 09 606),” . The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU 2014 09 January 1, 2017; 2015 14, 606) 2014 09 one January 1, 2018. March 2016, 2016 8, 606): 2014 09 2014 09. April 2016, 2016 10, may In August 2014, ASU No. 2014 15, one one December 15, 2016. In April 2015, 2015 03 835 30). 835 30 January 1, 2016 $3,517 $26,131 December 31, 2016 December 31, 2015, In January 2016, 2016 01, December 15, 2017. In February 2016, 2016 02, 842), twelve December 15, 2018, In March 2016, 2016 09, 718). December 15, 2016,

Note 3 - Short Term Investmen27

Note 3 - Short Term Investments Available for Sale (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Available-for-sale Securities [Table Text Block]	December 31, 201 6 December 31, 201 5 Cost Fair Value Cost Fair Value Short-term investments Certificate of deposit $ 1,680,000 $ 1,680,000 $ 4,800,000 $ 4,798,810 Bonds - corporate issuances – – 6,003,748 6,001,080 Total short-term investments $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890 December 31, 201 6 December 31, 201 5 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890 Between 3-12 months – – – – Total $ 1,680,000 $ 1,680,000 $ 10,803,748 $ 10,799,890
Investment Income [Table Text Block]	201 6 201 5 Interest and dividends accrued and paid $ 31,262 $ 186,322 Accretion of investment premium (3,808 ) (122,998 ) (Losses) gains on investment maturity and sales, net (532 ) 264 Investment income net $ 26,922 $ 63,588
Schedule of Unrealized Loss on Investments [Table Text Block]	December 31, 201 5 Description of Investment Securities Fair Value Unrealized Holding Gains (Losses) Available for sale (all unrealized holding gains and losses are less than 12 months at date of measurement) Short-term investments with unrealized gains – Certificates of deposit $ 240,024 $ 24 Short-term investments with unrealized losses – Certificates of deposit 4,558,786 (1,214 ) Short-term investments with unrealized losses – Bonds - corporate issuances 6,001,080 (2,668 ) Total $ 10,799,890 $ (3,858 )

Note 4 - Fair Values of Finan28

Note 4 - Fair Values of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total Fair Value on the Balance Sheet Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2016 Investment securities, available for sale $ 1,680,000 $ 1,680,000 $ ─ $ ─ Recurring items as of December 31, 2015 Investment securities, available for sale $ 10,799,890 $ 10,799,890 $ ─ $ ─ Liabilities: Recurring items as of December 31, 2016 Earn-out milestone liability (Note 12) $ 13,188,226 $ ─ $ ─ $ 13,188,226 Recurring items as of December 31, 2015 Earn-out milestone liability (Note 12) $ 13,921,412 $ ─ $ ─ $ 13,921,412

Note 5 - Acquisition of EGEN,29

Note 5 - Acquisition of EGEN, Inc. (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Property and equipment, net $ 35,000 In-process research and development 24,211,000 Other Intangible assets (Covenant not to compete) 1,591,000 Goodwill 1,976,000 Total assets: 27,813,000 Accounts payable and accrued liabilities (235,000 ) Net assets acquired $ 27,578,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended December 31, 2017 $ 227,316 2018 227,316 2019 227,316 2020 227,316 2021 113,660 Total $ 1,022,924

Note 6 - Property and Equipme30

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	Year E nded December 31, 201 6 201 5 Machinery and equipment (5-7 year life) $ 2,459,532 $ 2,398,613 Furniture and fixtures (3-5 year life) 246,507 244,923 Leasehold improvements (5-7 year life) 269,819 269,819 2,975,858 2,913,355 Less accumulated depreciation and amortization (2,513,022 ) (2,058,483 ) Total $ 462,836 $ 854,872

Note 7 - Other Accrued Liabil31

Note 7 - Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	Year E nded December 31, 2016 2015 Amounts due to contract research organizations and other contractual agreements $ 1,115,193 $ 571,615 Accrued payroll and related benefits 1,066,751 947,078 Accrued professional fees 259,550 319,200 Accrued interest on notes payable 22,241 62,136 Other 20,021 19,740 Total $ 2,483,756 $ 1,919,769

Note 8 - Notes Payable (Tables)

Note 8 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	As of December 31, 2017 $ 2,560,553 2018 and thereafter – Total $ 2,560,553

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2016 2015 Federal statutory rate 34.0 % 34.0 % State taxes, net of federal tax benefit 5.5 5.5 Recapture of alternative minimum tax – – Valuation allowance (39.5 ) (39.5 ) Effective tax rate – % – %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, In thousands 2016 2015 Net operating loss carry forwards $ 80,920 $ 71,557 Deferred tax assets, net 2,489 4,953 Subtotal 83,409 76,510 Valuation allowance (83,409 ) (76,510 ) Total deferred tax asset $ - $ -
Summary of Operating Loss Carryforwards [Table Text Block]	Approximate Amount of Unused Operating Loss Carry Forwards (in $000s) Expiration During Year Ended $ 7,136 2023 15,647 2024 8,168 2025 7,361 2026 11,905 2028 18,547 2029 18,145 2030 21,386 2031 20,558 2032 10,321 2033 22,906 2034 21,338 2035 21,444 2036 $ 204,862

Note 11 - Stock Based Compens34

Note 11 - Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2015 1,744,755 $ 7.20 Granted 839,250 2.35 Canceled or expired (444,183 ) 5.56 Outstanding at December 31, 2015 2,139,822 $ 5.64 Granted 846,283 1.29 Canceled or expired (53,442 ) 9.71 Outstanding at December 31, 2016 2,932,663 4.31 7.2 $ - Exercisable at December 31, 2016 2,198,907 $ 5.09 6.9 $ -
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Restricted Stock Number Outstanding Weighted Average Exercise Price Non-vested stock awards outstanding at January 1, 2015 7,018 $ 3.32 Granted 88,500 2.60 Vested and issued (14,000 ) 2.72 Non-vested stock awards outstanding at December 31, 2015 81,518 $ 2.64 Granted 112,000 1.63 Vested and issued (126,518 ) 1.72 Non-vested stock awards outstanding at December 31, 2016 67,000 * $ 2.67
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price $1.00 to 2.99 1,560,699 8.9 $ 1.77 857,897 8.9 $ 1.78 3.00 to 5.99 890,857 7.2 $ 3.81 859,903 7.2 $ 3.69 6.00 to 12.99 322,387 3.0 $ 10.82 322,387 3.0 $ 10.82 13.00 to 19.99 88,856 3.4 $ 14.19 88,856 3.4 $ 14.19 Above $20.00 69,864 1.2 $ 24.85 69,864 1.2 $ 24.85 2,932,663 2,198,907
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 201 6 201 5 Risk-free interest rate 1.55 to 1.87 % 1.57 to 2.93 % Expected volatility 87.5 - 89.1 % 92.9 - 104.1 % Expected life (in years) 10 10 Expected forfeiture rate 5 % 5 % Expected dividend yield 0.0 % 0.0 %

Note 12 - Earn-out Milestone 35

Note 12 - Earn-out Milestone Liability (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Changes in Earn out Milestone Liabilities [Table Text Block]	Balance at January 1, 2015 $ 13,663,710 Non-cash loss from the adjustment for the change in fair value included in 2015 net loss 257,702 Balance at December 31, 2015 $ 13,921,412 Non-cash gain from the adjustment for the change in fair value included in 2016 net loss (733,186 ) Balance at December 31, 2016 $ 13,188,226

Note 13 - Warrants (Tables)

Note 13 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Warrant Activity [Table Text Block]	Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2015 5,069,815 $ 8.18 Warrants issued in connection with the May 2015 equity transaction 1,950,000 $ 2.60 Warrants expired during 2015 (1,125,140 ) $ 7.98 Warrants outstanding at December 31, 2015 5,894,675 $ 6.37 Warrants issued in connection with the 2016 equity transactions 16,066,371 $ 0.92 Warrants exercised during 2016 (250,000 ) $ 0.01 Warrants expired during 2016 (879,163 ) $ 14.94 Warrants outstanding at December 31, 2016 20,831,883 $ 1.88 Aggregate intrinsic value of outstanding warrants at December 31, 2016 $ 534,000 Weighted average remaining contractual terms (years) 3.32 (1)

Note 17 - Contingent Liabilit37

Note 17 - Contingent Liabilities and Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	For the year ending December 31: Operating Leases 2017 $ 378,042 2018 23,200 2019 — 2020 and beyond — Total minimum lease payments $ 401,242

Note 1 - Summary of Significa38

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 455,000	$ 425,000
Finite-Lived Patents, Gross	75,000
Finite-Lived Intangible Assets, Accumulated Amortization	$ 75,000	$ 69,375
Finite-Lived Intangible Asset, Useful Life	10 years
Number of Shares of Common Stock Issuable Upon Exercise of Warrants and Equity Awards	23,831,883	8,116,015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,984,210
Debt Issuance Costs, Noncurrent, Net	$ 3,517	$ 26,131
Series B Warrant [Member]
Weighted Average Number of Shares, Contingently Issuable	1,850,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Note 2 - Financial Condition 39

Note 2 - Financial Condition and Going Concern (Details Textual) - USD ($)	Feb. 14, 2017	Oct. 02, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Net Income (Loss) Attributable to Parent			$ (22,053,726)	$ (22,461,084)
Net Cash Provided by (Used in) Operating Activities			(18,379,364)	(20,830,563)
Retained Earnings (Accumulated Deficit)			(241,379,712)	$ (218,130,360)	$ (241,379,712)
Cash, Cash Equivalents, and Short-term Investments			4,300,000		4,300,000
Notes Payable			2,600,000		2,600,000
February 2017 Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock Gross	$ 5,000,000
ATM Agreement [Member]
Proceeds from Issuance of Common Stock Gross					$ 7,600,000
Aggregate Offering Price, Additions		$ 7,500,000	$ 7,500,000

Note 3 - Short Term Investmen40

Note 3 - Short Term Investments Available for Sale (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Short-term Investments	$ 1,680,000	$ 10,799,890
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	0
Short Term Investments Available for Sale [Member]
Short-term Investments	$ 1,680,000	$ 10,799,890

Note 3 - Short Term Investmen41

Note 3 - Short Term Investments Available for Sale - Short-term Investment by Bond Maturities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Short-term investments, fair value		$ 10,799,890
Total short-term investments	$ 1,680,000	10,803,748
Total short-term investments	1,680,000	10,799,890
Certificate of Deposit [Member]
Short-term investments, cost	1,680,000	4,800,000
Short-term investments, fair value	1,680,000	4,798,810
Investment Maturing Within Three Months [Member]
Total short-term investments	1,680,000	10,803,748
Total short-term investments	1,680,000	10,799,890
Corporate Debt Securities [Member]
Short-term investments, cost		6,003,748
Short-term investments, fair value		6,001,080
Investment Maturing Between 3 and 12 Months [Member]
Total short-term investments
Total short-term investments

Note 3 - Short Term Investmen42

Note 3 - Short Term Investments Available for Sale - Available for Sale - Investment Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Interest and dividends accrued and paid	$ 31,262	$ 186,322
Accretion of investment premium	(3,808)	(122,998)
(Losses) gains on investment maturity and sales, net	(532)	264
Investment income net	$ 26,922	$ 63,588

Note 3 - Short Term Investmen43

Note 3 - Short Term Investments Available for Sale - Investment Securities Gross Unrealized Losses and Fair Value by Investment Category (Details)	Dec. 31, 2015USD ($)
Available for sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Total	$ 10,799,890
Total	(3,858)
Certificates of Deposit [Member]
Available for sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	240,024
Short-term investments with unrealized gains	24
Short-term investments with unrealized losses	4,558,786
Short-term investments with unrealized losses	(1,214)
Corporate Bond Securities [Member]
Available for sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized losses	6,001,080
Short-term investments with unrealized losses	$ (2,668)

Note 4 - Fair Values of Finan44

Note 4 - Fair Values of Financial Instruments (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3	$ 0	$ 0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3	0	0
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	0	0
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	$ 0	$ 0

Note 4 - Fair Values of Finan45

Note 4 - Fair Values of Financial Instruments - Assets and Liabilities at Fair Value on a Recurring Basis (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Investment securities, available for sale		$ 10,799,890
Earn-out milestone liability	$ 13,188,226	13,921,412
Fair Value, Measurements, Recurring [Member]
Investment securities, available for sale	1,680,000	10,799,890
Earn-out milestone liability	13,188,226	13,921,412
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Investment securities, available for sale	1,680,000	10,799,890
Earn-out milestone liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Investment securities, available for sale
Earn-out milestone liability	$ 13,188,226	$ 13,921,412

Note 5 - Acquisition of EGEN,46

Note 5 - Acquisition of EGEN, Inc. (Details Textual) - USD ($)	Sep. 30, 2014	Jun. 20, 2014	Jun. 10, 2014	Jun. 09, 2014	Nov. 30, 2013	Jun. 10, 2014	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Aug. 02, 2016
Gain (Loss) from Valuation of Milestone Liability								$ 733,186	$ (257,702)
Finite-Lived Intangible Asset, Useful Life								10 years
Finite-Lived Intangible Assets, Accumulated Amortization								$ 75,000	69,375
Finite-Lived Intangible Assets, Net								1,022,924	1,591,214
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Accumulated Amortization								568,290
Finite-Lived Intangible Assets, Net								1,022,924	$ 1,591,214
Indefinite-lived in Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)								1,400,000
Hercules [Member] | Hercules Credit Agreement [Member]
Proceeds from Lines of Credit				$ 5,000,000	$ 5,000,000	$ 10,000,000
EGEN Inc [Member]
Business Combination, Consideration Transferred		$ 27,600,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		30,400,000						$ 30,400,000
Payments to Acquire Businesses, Gross		$ 3,000,000
Stock Issued During Period, Shares, Acquisitions	2,712,188	2,712,188
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	670,070						670,070
Goodwill, Acquired During Period		$ 2,000,000
EGEN Inc [Member] | Noncompete Agreements [Member]
Finite-lived Intangible Assets Acquired		$ 1,600,000
Finite-Lived Intangible Asset, Useful Life		7 years
EGEN Inc [Member] | Indefinite-lived in Process Research and Development [Member]
Indefinite-lived Intangible Assets Acquired		$ 24,200,000
EGEN Inc [Member] | Hercules Credit Agreement [Member]
Payments to Acquire Businesses, Gross			$ 3,000,000
EGEN Inc [Member] | Ovarian Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High										$ 12,400,000
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High										12,000,000
EGEN Inc [Member] | TheraSilence Technology Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High										$ 6,000,000
EGEN Inc [Member] | Maximum [Member]
Business Combination, Consideration Transferred		$ 44,400,000

Note 5 - Acquisition of EGEN,47

Note 5 - Acquisition of EGEN, Inc. - Summary of Estimated Fair Values of Acquired Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Jun. 20, 2014
Goodwill	$ 1,976,101	$ 1,976,101
EGEN Inc [Member]
Property and equipment, net			$ 35,000
In-process research and development			24,211,000
Other Intangible assets (Covenant not to compete)			1,591,000
Goodwill			1,976,000
Total assets:			27,813,000
Accounts payable and accrued liabilities			(235,000)
Net assets acquired			$ 27,578,000

Note 5 - Acquisition of Egen,48

Note 5 - Acquisition of Egen, Inc. - Amortization Schedule for Covenant Not to Complete (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Total	$ 1,022,924	$ 1,591,214
Noncompete Agreements [Member]
2,017	227,316
2,018	227,316
2,019	227,316
2,020	227,316
2,021	113,660
Total	$ 1,022,924	$ 1,591,214

Note 6 - Property and Equipme49

Note 6 - Property and Equipment - Property, Plant, and Equipment Useful Life (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant, And Equipment, Gross	$ 2,975,858	$ 2,913,355
Less accumulated depreciation and amortization	(2,513,022)	(2,058,483)
Total	462,836	854,872
Machinery and Equipment [Member]
Property, Plant, And Equipment, Gross	2,459,532	2,398,613
Furniture and Fixtures [Member]
Property, Plant, And Equipment, Gross	246,507	244,923
Leasehold Improvements [Member]
Property, Plant, And Equipment, Gross	$ 269,819	$ 269,819

Note 6 - Property and Equipme50

Note 6 - Property and Equipment - Property, Plant, and Equipment Useful Life (Details) (Parentheticals) - Minimum [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Estimated Useful Life (Year)	3 years
Machinery and Equipment [Member]
Estimated Useful Life (Year)	5 years	7 years
Furniture and Fixtures [Member]
Estimated Useful Life (Year)	3 years	5 years
Leasehold Improvements [Member]
Estimated Useful Life (Year)	5 years	7 years

Note 7 - Other Accrued Liabil51

Note 7 - Other Accrued Liabilities - Other Accrued Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Amounts due to contract research organizations and other contractual agreements	$ 1,115,193	$ 571,615
Accrued payroll and related benefits	1,066,751	947,078
Accrued professional fees	259,550	319,200
Accrued interest on notes payable	22,241	62,136
Other	20,021	19,740
Total	$ 2,483,756	$ 1,919,769

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	Jun. 20, 2014	Jun. 10, 2014	Jun. 10, 2014	Jun. 09, 2014	Nov. 25, 2013	Dec. 31, 2016	Nov. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 10, 2014	Dec. 31, 2016	Dec. 15, 2016	Dec. 31, 2015	Dec. 17, 2015	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument, Basis Spread on Variable Rate						11.75%						11.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.88					$ 1.88		$ 6.37		$ 1.88	$ 8.18
Increase (Decrease) in Other Operating Assets											$ 733,186		$ (257,702)
Gain (Loss) From Change In Valuation Of Common Stock Warrant Liability													(61,246)
Common Stock Warrant Liability								$ 0
Hercules Warrant [Member]
Debt Issuance Costs, Net																	$ 521,763
Fair Value Assumptions, Expected Volatility Rate			104.00%
Fair Value Assumptions, Risk Free Interest Rate			1.69%
Fair Value Assumptions, Expected Term			4 years 182 days
Share Price				$ 3.07
Increase (Decrease) in Other Operating Assets									$ (521,763)
Gain (Loss) From Change In Valuation Of Common Stock Warrant Liability								(18,018)					(61,246)
Classification of Warrants to (from) Common Stock Warrant Liability Net								$ (336,254)
Hercules Warrant [Member] | First Fifty Percent [Member]
Debt Instrument, Unamortized Discount									$ 260,928
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									97,493
Hercules Warrant [Member] | Second Fifty Percent [Member]
Debt Instrument, Unamortized Discount				$ 215,333
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				97,493
EGEN Inc [Member]
Payments to Acquire Businesses, Gross	$ 3,000,000
Hercules Credit Agreement [Member]
Repayments of Lines of Credit							$ 4,000,000
Interest Expense, Debt											486,327		918,465
Amortization of Debt Issuance Costs											236,666		$ 438,717
Hercules Credit Agreement [Member] | Hercules Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 3.59
Fair Value Assumptions, Expected Volatility Rate					102.00%
Fair Value Assumptions, Risk Free Interest Rate					1.37%
Fair Value Assumptions, Expected Term					5 years
Share Price					$ 3.55
Line of Credit Facility Original Loan Fee Percent								3.50%
Debt Issuance Costs, Gross								$ 350,000
Hercules Credit Agreement [Member] | Hercules Warrant [Member] | First Fifty Percent [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					97,493
Hercules Credit Agreement [Member] | Hercules Warrant [Member] | Second Fifty Percent [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		97,493	97,493							97,493
Hercules Credit Agreement [Member] | EGEN Inc [Member]
Payments to Acquire Businesses, Gross		$ 3,000,000
Hercules [Member]
Repayments of Lines of Credit		$ 5,000,000
Hercules [Member] | Hercules Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity							20,000,000
Proceeds from Lines of Credit				$ 5,000,000			5,000,000			$ 10,000,000
Debt Instrument, Basis Spread on Variable Rate														11.25%
Amortization Period for Principal and Interest															2 years 180 days
Debt Issuance Costs, Net						$ 122,378					$ 122,378				$ 122,378
Debt Instrument, Unamortized Discount							$ 230,000

Note 8 - Notes Payable - Future

Note 8 - Notes Payable - Future Principal Payments Due on the Credit Agreement (Details) - Hercules Credit Agreement [Member]	Dec. 31, 2016USD ($)
2,017	$ 2,560,553
2018 and thereafter
Total	$ 2,560,553

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Millions	Jul. 25, 2011	Jun. 03, 2013	Feb. 05, 2013	Jun. 01, 2015	Dec. 31, 2016
Operating Loss Carryforwards	$ 90	$ 34	$ 34	$ 31	$ 85.6
Operating Loss Carry Forwards, Limitation on Use	$ 4.9	$ 1.5	$ 1.4	$ 1.6

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of the Company's Statutory Tax Rate to the Effective Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Federal statutory rate	34.00%	34.00%
State taxes, net of federal tax benefit	5.50%	5.50%
Recapture of alternative minimum tax
Valuation allowance	(39.50%)	(39.50%)
Effective tax rate

Note 9 - Income Taxes - Compone

Note 9 - Income Taxes - Components of the Company's Deferred Tax Asset (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carry forwards	$ 80,920	$ 71,557
Deferred tax assets, net	2,489	4,953
Subtotal	83,409	76,510
Valuation allowance	(83,409)	(76,510)
Total deferred tax asset

Note 9 - Income Taxes - Approxi

Note 9 - Income Taxes - Approximate Amount of Unused Operating Loss Carry Forwards and Expiration Dates (Details) $ in Thousands	Dec. 31, 2016USD ($)
Operating Loss Carryforwards	$ 204,862
Expires 2023 [Member]
Operating Loss Carryforwards	7,136
Expires 2024 [Member]
Operating Loss Carryforwards	15,647
Expires 2025 [Member]
Operating Loss Carryforwards	8,168
Expires 2026 [Member]
Operating Loss Carryforwards	7,361
Expires 2028 [Member]
Operating Loss Carryforwards	11,905
Expires 2029 [Member]
Operating Loss Carryforwards	18,547
Expires 2030 [Member]
Operating Loss Carryforwards	18,145
Expires 2031 [Member]
Operating Loss Carryforwards	21,386
Expires 2032 [Member]
Operating Loss Carryforwards	20,558
Expires 2033 [Member]
Operating Loss Carryforwards	10,321
Expires 2034 [Member]
Operating Loss Carryforwards	22,906
Expires 2035 [Member]
Operating Loss Carryforwards	21,338
Expires 2036 [Member]
Operating Loss Carryforwards	$ 21,444

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details Textual) - USD ($)	Dec. 20, 2016	Jun. 13, 2016	Oct. 02, 2015	May 27, 2015	Sep. 30, 2014	Jun. 20, 2014	Jan. 15, 2014	Feb. 01, 2013	Sep. 30, 2015	Feb. 25, 2013	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2016	Jun. 30, 2016	May 31, 2016	Dec. 31, 2014
Shelf Registration Statement Amount									$ 75,000,000
Common Stock, Shares Authorized													112,500,000	112,500,000	112,500,000	112,500,000	112,500,000	75,000,000
Preferred Stock, Shares Authorized													100,000	100,000	100,000	100,000	100,000
Aggregate of Common and Preferred Stock, Shares Authorized																	112,600,000
Class of Warrant or Right, Outstanding													20,831,883	5,894,675	20,831,883	20,831,883			5,069,815
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 1.88	$ 6.37	$ 1.88	$ 1.88			$ 8.18
Common Stock, Par or Stated Value Per Share													$ 0.01	$ 0.01	$ 0.01	$ 0.01
Proceeds from Warrant Exercises													$ 2,500		$ 0
Proceeds from Stock Options Exercised															$ 0
EGEN Inc [Member]
Stock Issued During Period, Shares, Acquisitions					2,712,188	2,712,188
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares					670,070							670,070
Common Stock [Member]
Stock Issued During Period, Shares, New Issues													126,518	14,000
June 2016 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues		2,311,764
Share Price		$ 1.36
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		8,823,528
Maximum Beneficial Ownership of the Purchaser		9.99%
Proceeds from Issuance of Common Stock Gross		$ 6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.40
Ownership Percentage, Restriction Threshold for Warrant Exercise		4.99%
Number of Days Notice Requirement to Increase or Decrease Beneficial Ownership Limitation		61 days
Common Stock Offering Period of Restriction		180 days
June 2016 Common Stock Offering [Member] | Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,100,000
Class of Warrant or Right, Outstanding													1,850,000		1,850,000	1,850,000
June 2016 Common Stock Offering [Member] | Series B Warrant [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Exercise of Warrants											250,000
June 2016 Common Stock Offering [Member] | Series A Warrant [Member]
Class of Warrant or Right, Outstanding		1,850,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.5
Warrants Exercisable Period		180 days
Warrants Issued Expiration Period		5 years 182 days
June 2016 Common Stock Offering [Member] | Series C Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Warrants Exercisable Period		180 days
Warrants Issued Expiration Period		1 year
June 2016 Common Stock Offering [Member] | Series D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.5
Warrants Exercisable Period		180 days
Warrants Issued Expiration Period		5 years 182 days
December 2016 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues	5,142,843
Share Price	$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,142,843
Maximum Beneficial Ownership of the Purchaser	9.99%
Proceeds from Issuance of Common Stock Gross	$ 1,800,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Warrants Exercisable Period	180 days
Warrants Issued Expiration Period	5 years 182 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.46
Number of Days Notice Requirement to Increase or Decrease Beneficial Ownership Limitation	61 days
May 2015 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues				3,000,000
Share Price				$ 2.675
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,950,000
Proceeds from Issuance of Common Stock Gross				$ 8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				0.65
Warrants Issued Expiration Period				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.60
Common Stock Offering Period of Restriction				150 days
January 2014 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues							3,603,604
Share Price							$ 4.1625
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,801,802
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4.10
Common Stock Offering Period of Restriction							270 days
Common Stock, Par or Stated Value Per Share							$ 0.01
Stock Issued During Period, Value, New Issues							$ 15,000,000
Common Stock Shares per Unit							1
January 2014 Common Stock Offering [Member] | Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							0.25
Warrants Issued Expiration Period							1 year
January 2014 Common Stock Offering [Member] | Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							0.25
Warrants Issued Expiration Period							5 years
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues																1,479,535
Proceeds from Issuance of Common Stock Gross																$ 7,600,000
Aggregate Offering Price								$ 25,000,000					$ 17,400,000
Commission on Proceeds from ATM Shares Percent										3.00%
Legal Fees										$ 50,000
Aggregate Offering Price, Additions			$ 7,500,000										$ 7,500,000

Note 11 - Stock Based Compens59

Note 11 - Stock Based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2004	Dec. 31, 2001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,932,663	2,139,822	1,744,755
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	7 years 73 days
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						95,555
Stock Incentive Plan 2001 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								148,148
Stock Incentive Plan 2004 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							148,148
Stock Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			3,444,444	944,444	444,444	222,222
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			2,500,000	500,000	222,222
Percentage of Fair Market Value of Shares			100.00%
Percentage of Outstanding Stock Determining Factor for Incentive Stock Price			10.00%
Allocated Share-based Compensation Expense	$ 1,500,000	$ 1,800,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	255 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.16	$ 2.05
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 0	$ 0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,533,752
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	2,999,663
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	534,089
Issued to Consultants For Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	255 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested	$ 21,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Minimum [Member] | Stock Incentive Plan 2007 [Member]
Percentage of Fair Market Value of Shares			110.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years

Note 11 - Stock Based Compens60

Note 11 - Stock Based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding at January 1, 2015 (in shares)	2,139,822	1,744,755
Outstanding at January 1, 2015 (in dollars per share)	$ 5.64	$ 7.20
Granted (in shares)	846,283	839,250
Granted (in dollars per share)	$ 1.29	$ 2.35
Canceled or expired (in shares)	(53,442)	(444,183)
Canceled or expired (in dollars per share)	$ 9.71	$ 5.56
Outstanding at December 31, 2016 (in shares)	2,932,663	2,139,822
Outstanding at December 31, 2016 (in dollars per share)	$ 4.31	$ 5.64
Outstanding at December 31, 2016 (Year)	7 years 73 days
Exercisable at December 31, 2016 (in shares)	2,198,907
Exercisable at December 31, 2016 (in dollars per share)	$ 5.09
Exercisable at December 31, 2016 (Year)	6 years 328 days

Note 11 - Stock Based Compens61

Note 11 - Stock Based Compensation - Summary of the Status of the Company's Non-vested Restricted Stock Awards (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Non-vested stock awards outstanding at January 1, 2015 (in shares)	81,518	7,018
Non-vested stock awards outstanding at January 1, 2015 (in dollars per share)	$ 2.64	$ 3.32
Granted (in shares)	112,000	88,500
Granted (in dollars per share)	$ 1.63	$ 2.60
Vested and issued (in shares)	(126,518)	(14,000)
Vested and issued (in dollars per share)	$ 1.72	$ 2.72
Non-vested stock awards outstanding at December 31, 2015 (in shares)	67,000	81,518
Non-vested stock awards outstanding at December 31, 2015 (in dollars per share)	$ 2.67	$ 2.64
Vested and issued (in shares)	(126,518)	(14,000)

Note 11 - Stock Based Compens62

Note 11 - Stock Based Compensation - Summary of Stock Option Awards and Changes (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Options Outstanding, Number (in Shares) (in shares)	2,932,663	2,139,822	1,744,755
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.31	$ 5.64	$ 7.20
Options Exercisable, Number (in Shares) (in shares)	2,198,907
Exercisable at December 31, 2016 (Year)	6 years 328 days
Range 1 [Member]
Range of Exercise Prices, Lower Range (in dollars per share)	$ 1
Range of Exercise Prices, Upper Range (in dollars per share)	$ 2.99
Options Outstanding, Number (in Shares) (in shares)	1,560,699
Options Outstanding, Weighted Average Remaining Contractual Term (in years) (Year)	8 years 328 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 1.77
Options Exercisable, Number (in Shares) (in shares)	857,897
Exercisable at December 31, 2016 (Year)	8 years 328 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.78
Range 2 [Member]
Range of Exercise Prices, Lower Range (in dollars per share)	3
Range of Exercise Prices, Upper Range (in dollars per share)	$ 5.99
Options Outstanding, Number (in Shares) (in shares)	890,857
Options Outstanding, Weighted Average Remaining Contractual Term (in years) (Year)	7 years 73 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.81
Options Exercisable, Number (in Shares) (in shares)	859,903
Exercisable at December 31, 2016 (Year)	7 years 73 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.69
Range 3 [Member]
Range of Exercise Prices, Lower Range (in dollars per share)	6
Range of Exercise Prices, Upper Range (in dollars per share)	$ 12.99
Options Outstanding, Number (in Shares) (in shares)	322,387
Options Outstanding, Weighted Average Remaining Contractual Term (in years) (Year)	3 years
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 10.82
Options Exercisable, Number (in Shares) (in shares)	322,387
Exercisable at December 31, 2016 (Year)	3 years
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 10.82
Range 4 [Member]
Range of Exercise Prices, Lower Range (in dollars per share)	13
Range of Exercise Prices, Upper Range (in dollars per share)	$ 19.99
Options Outstanding, Number (in Shares) (in shares)	88,856
Options Outstanding, Weighted Average Remaining Contractual Term (in years) (Year)	3 years 146 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 14.19
Options Exercisable, Number (in Shares) (in shares)	88,856
Exercisable at December 31, 2016 (Year)	3 years 146 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 14.19
Range 5 [Member]
Range of Exercise Prices, Lower Range (in dollars per share)	$ 20
Options Outstanding, Number (in Shares) (in shares)	69,864
Options Outstanding, Weighted Average Remaining Contractual Term (in years) (Year)	1 year 73 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 24.85
Options Exercisable, Number (in Shares) (in shares)	69,864
Exercisable at December 31, 2016 (Year)	1 year 73 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 24.85

Note 11 - Stock Based Compens63

Note 11 - Stock Based Compensation - Fair Value of Option Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Minimum [Member]
Risk-free interest rate		1.57%
Expected volatility		92.90%
Maximum [Member]
Risk-free interest rate		2.93%
Expected volatility		104.10%
Expected life (in years) (Year)		10 years
Expected forfeiture rate		5.00%
Expected dividend yield		0.00%
Employee Stock Option [Member] | Minimum [Member]
Risk-free interest rate	1.55%
Expected volatility	87.50%
Employee Stock Option [Member] | Maximum [Member]
Risk-free interest rate	1.87%
Expected volatility	89.10%
Expected life (in years) (Year)	10 years
Expected forfeiture rate	5.00%
Expected dividend yield	0.00%

Note 12 - Earn-out Milestone 64

Note 12 - Earn-out Milestone Liability (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 20, 2014	Dec. 31, 2016	Dec. 31, 2015
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability			$ (733,186)	$ 257,702
EGEN Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 30,400,000	30,400,000
Business Combination, Consideration Transferred, Liabilities Incurred	$ 13,700,000	$ 13,900,000	13,200,000	13,900,000
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability			$ 700,000	$ 257,702
EGEN Inc [Member] | Minimum [Member]
Risk Adjusted Assessment of Each Milestone		10.00%	50.00%	10.00%
Estimated Time to Achieve the Milestone		1 year 182 days	2 years	1 year 73 days
EGEN Inc [Member] | Maximum [Member]
Risk Adjusted Assessment of Each Milestone		67.00%	80.00%	67.00%
Estimated Time to Achieve the Milestone		2 years 182 days	2 years 182 days	6 years 182 days

Note 12 - Earn-out Milestone 65

Note 12 - Earn-out Milestone Liability - Summary of the Changes in the Earn-out Milestone Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 13,921,412	$ 13,663,710
Non-cash loss from the adjustment for the change in fair value	(733,186)	257,702
Balance at December 31, 2016	$ 13,188,226	$ 13,921,412

Note 13 - Warrants (Details Tex

Note 13 - Warrants (Details Textual) - USD ($)	3 Months Ended	12 Months Ended		24 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Jun. 13, 2016	Dec. 31, 2014	Nov. 30, 2013
Number Of Warrants Issued		16,066,371	1,950,000
Class of Warrant or Right, Outstanding		20,831,883	5,894,675	20,831,883		5,069,815
Proceeds from Stock Options Exercised				$ 0
Proceeds from Warrant Exercises		$ 2,500		$ 0
June 2016 Common Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					8,823,528
Hercules Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							194,986
Series B Warrant [Member] | June 2016 Common Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,100,000
Class of Warrant or Right, Outstanding		1,850,000		1,850,000
Series B Warrant [Member] | June 2016 Common Stock Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Exercise of Warrants	250,000
Series A Warrant [Member] | June 2016 Common Stock Offering [Member]
Class of Warrant or Right, Outstanding					1,850,000

Note 13 - Warrants - Summary of

Note 13 - Warrants - Summary of Warrant Activity (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Warrants outstanding (in shares)		5,894,675	5,069,815
Warrants outstanding (in dollars per share)		$ 6.37	$ 8.18
Warrants issued in connection with the May 2015 equity transaction (in shares)		16,066,371	1,950,000
Warrants issued in connection with the May 2015 equity transaction (in dollars per share)		$ 0.92	$ 2.60
Warrants expired during 2015 (in shares)		(879,163)	(1,125,140)
Warrants expired during 2015 (in dollars per share)		$ 14.94	$ 7.98
Warrants outstanding (in shares)		20,831,883	5,894,675
Warrants outstanding (in dollars per share)		$ 1.88	$ 6.37
Warrants exercised during 2016 (in shares)		(250,000)
Warrants exercised during 2016 (in dollars per share)		$ 0.01
Aggregate intrinsic value of outstanding warrants		$ 534,000
Weighted average remaining contractual terms (Year)	[1]	3 years 116 days
[1]	Does not include the remaining Pre-Funded Warrants issued in the June 2016 Offering (totaling 1,850,000 shares underlying these warrants) as these warrants have no expiration date.

Note 14 - Celsion Employee Be68

Note 14 - Celsion Employee Benefit Plans (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Minimum Age For Employee Benefit Plan	21
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	3.00%
Defined Benefit Plan, Contributions by Employer	$ 82,391	$ 80,408

Note 15 - Licenses of Intelle69

Note 15 - Licenses of Intellectual Property and Patents (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Jan. 31, 2003USD ($)shares
Number Of Days Before Issuance Factoring Into Average Closing Price	20 days
Amount of Time after Effective Date of License Agreement for Registration Rights to Take Place	1 year
Common Stock, Shares, Issued | shares	31,226,336	23,395,211	253,691
Common Stock, Value, Issued | $	$ 312,263	$ 233,952	$ 2,200,000
Number Of Trademark Protection Application Pending For Thermo Dox	14

Note 16 - Technology Developm70

Note 16 - Technology Development and Licensing Agreements (Details Textual) - USD ($)	Jan. 18, 2013	Mar. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Contractual Obligation			$ 1,115,193	$ 571,615
Deferred Revenue		$ 5,000,000
Deferred Revenue Amortization Period		10 years
Hisun [Member]
Contractual Obligation					$ 685,787
Proceeds from License Fees Received	$ 5,000,000

Note 17 - Contingent Liabilit71

Note 17 - Contingent Liabilities and Commitments (Details Textual)	1 Months Ended						12 Months Ended
	Apr. 30, 2015USD ($)	Jun. 30, 2014USD ($)ft²	Apr. 30, 2014USD ($)	Apr. 30, 2013USD ($)	Apr. 30, 2012USD ($)	Jul. 31, 2011ft²	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Payments for Rent							$ 575,516	$ 570,078
Contractual Obligation							$ 1,115,193	$ 571,615
Standby Letters of Credit [Member]
Contractual Obligation Reduction Nineteen Months from Initial Term					$ 50,000
Contractual Obligation Remaining					100,000
Contractual Obligation Reduction Thirty One Months from Initial Term					50,000
Contractual Obligation Reduction Forty Three Months from Initial Term					50,000
Lawrenceville New Jersey [Member]
Area of Real Estate Property | ft²		11,500				10,870
Lessee Leasing Arrangements, Operating Leases, Term of Contract						5 years 180 days
Number of Months in Which Free Rent Is Provided						180 days
Payments for Rent					23,000
Reduction of Escrow Deposit	$ 50,000		$ 50,000	$ 50,000
Lawrenceville New Jersey [Member] | Standby Letters of Credit [Member]
Contractual Obligation					$ 250,000
Premises Located in Huntsville Alabama [Member]
Lessee Leasing Arrangements, Operating Leases, Term of Contract		13 years
Operating Leases Monthly Rent Payment		$ 23,200

Note 17 - Contingent Liabilit72

Note 17 - Contingent Liabilities and Commitments - Summary of the Future Minimum Payments Required Under Leases (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 378,042
2,018	23,200
2,019
2020 and beyond
Total minimum lease payments	$ 401,242

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Feb. 14, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.88	$ 6.37	$ 8.18
February 2017 Public Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	19,385,869
Share Price	$ 0.23
Proceeds from Issuance of Common Stock Gross	$ 5
February 2017 Public Offering [Member] | Subsequent Event [Member] | Series AA Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,489,402
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.23
Warrants Issued Expiration Period	5 years
February 2017 Public Offering [Member] | Subsequent Event [Member] | Pre-Funded Series BB Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Class of Warrant or Right, Offered Price of Warrants or Rights	$ 0.22